Welcome to our dedicated page for Balchem SEC filings (Ticker: BCPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Balchem Corporation filings document financial results, governance matters, shareholder votes, and material events for a specialty ingredient manufacturer with Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments. Form 8-K reports attach quarterly and annual earnings releases with segment performance, cash flow measures, balance sheet items, debt, and capital-allocation disclosures.
Proxy and shareholder-meeting filings describe board elections, auditor ratification, advisory executive-compensation votes, meeting procedures, corporate governance practices, and executive compensation. Other material-event reports record officer transitions and related governance disclosures, while exhibit and Inline XBRL records support the company’s public reporting framework.
Balchem Corporation appointed Erin L. Gilson as Vice President and Chief Accounting Officer, effective April 1, 2026. She succeeds William A. Backus, whose retirement from the same role on March 31, 2026 had been previously announced.
Gilson has been with Balchem since February 2016 and currently serves as Senior Director of Accounting and Financial Reporting. The company states there are no material changes to her compensatory arrangement in connection with this election.
Balchem Corporation senior executive Job Leonard van Gunsteren reported multiple equity compensation transactions. On February 11, 2026, he received 430 shares of restricted stock that vest over three years and 1,345 common shares from vesting performance stock units for the 2023–2025 performance period.
To cover tax obligations upon vesting, 756 shares were withheld at $178.68 per share on February 11 and 58 shares were withheld at $177.49 per share on February 12. He was also granted 1,600 stock options at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three. After these transactions he directly owns 10,149 common shares and 1,600 stock options.
Reid Martin Luther reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 7,900 shares at a weighted average price of $178.57 per share. Following the reported transactions, holdings were 9,073 shares.
Harris Theodore L reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 62,743 shares at a weighted average price of $178.58 per share. Following the reported transactions, holdings were 91,373 shares.
BCPC senior executive Graham George reported equity awards from the company. As SVP and Chief R&D Officer, he received a grant of 700 shares of common stock at a price of $0, increasing his directly held common stock to 3,200 shares, plus 20 shares held indirectly through a 401(k) plan.
The filing also shows a stock option grant for 2,600 shares of common stock with an exercise price of $178.68 per share, expiring on 02/11/2036. The restricted stock vests over three years (25%, 25%, 50%), while the options vest 20% in year one, 40% in year two, and 40% in year three.
Backus William A. reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 4,889 shares at a weighted average price of $178.59 per share. Following the reported transactions, holdings were 6,736 shares.
BCPC senior vice president Frederic Boned reported new equity awards and related tax share withholdings. On February 11, he acquired 2,870 shares of restricted common stock and 2,247 common shares from performance stock units vesting for the 2023–2025 period.
To cover tax obligations, 1,151 of those vested shares were withheld at $178.68 per share on February 11 and an additional 203 shares were withheld at $177.49 per share on February 12. He was also granted stock options for 10,500 shares at a $178.68 exercise price, vesting over three years and expiring on February 11, 2036. After these transactions, he directly owned 8,978 common shares, plus 441 shares held indirectly in a 401(k) plan and 10,500 stock options.
BCPC senior vice president and Chief HR Officer Michael Brent Tignor reported multiple equity compensation transactions. On February 11, 2026, he acquired 1,200 shares of restricted common stock at $0, vesting over three years, and 1,929 shares from vested performance stock units for the 2023–2025 period, including 31 dividend equivalent shares.
To cover tax obligations on these vestings, 991 shares were withheld at $178.68 on February 11, 2026 and 165 shares were withheld at $177.49 on February 12, 2026. He also received a stock option for 4,400 shares at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three, expiring on February 11, 2036. Following these transactions he directly held 10,723 common shares, plus 1,456 shares indirectly through a 401(k) plan and 4,400 stock options.
BCPC executive Hatsuki Miyata, EVP, CLO & Secretary, reported several equity compensation transactions. On February 11, 2026, Miyata acquired 1,710 shares of common stock as restricted stock that vests over three years and 2,247 shares from performance stock units for the 2023–2025 period.
To cover related tax liabilities, 877 shares were withheld at $178.68 per share on February 11 and 181 shares were withheld at $177.49 per share on February 12. Miyata also received a grant of 6,300 stock options at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three.
After these transactions, Miyata directly held 8,745 common shares and indirectly held 487 shares through a 401(k) plan, in addition to the 6,300 stock options.
Balchem Corporation executive Carl Martin Bengtsson, EVP & Chief Financial Officer, reported multiple equity compensation transactions and related tax withholdings. On February 11, 2026 he acquired 3,610 shares of common stock as restricted stock and 4,718 shares from vested performance stock units at no cost, while 2,416 of those vested units were withheld to satisfy tax obligations. He also received a stock option grant for 13,200 shares at an exercise price of $178.68 per share, vesting 20% in year one, 40% in year two, and 40% in year three, expiring in 2036. Additional shares were withheld on February 12, 2026 to cover taxes on previously granted restricted shares. After these transactions, he directly held 27,926 common shares, plus 1,086 shares held indirectly in a 401(k) plan, along with 13,200 stock options.